Pregabalin for generalized anxiety disorder
| Autor: | Marcelo B. Generoso, Siegfried Kasper, Alisson Paulino Trevizol, Quirino Cordeiro, Hyong Jin Cho, Pedro Shiozawa |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Funnel plot
medicine.medical_specialty Generalized anxiety disorder Pregabalin Placebo 03 medical and health sciences 0302 clinical medicine Internal medicine Humans Medicine Pharmacology (medical) Clinical Trials as Topic business.industry Publication bias medicine.disease Anxiety Disorders Confidence interval 030227 psychiatry Psychiatry and Mental health Anti-Anxiety Agents Meta-analysis Anxiety medicine.symptom business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | International Clinical Psychopharmacology. 32:49-55 |
| ISSN: | 0268-1315 |
| DOI: | 10.1097/yic.0000000000000147 |
| Popis: | Generalized anxiety disorder (GAD), characterized by pervasive and highly distressing anxiety and worries, is associated with severe impairment. Although numerous agents from various drug classes are available to treat GAD, as many as 50% of patients have inadequate response, constituting an important medical frontier. In the face of this challenge, new pharmacological alternatives need to be further studied aiming at clinical improvement and better quality of life for patients. To assess the efficacy of pregabalin (PGB) compared with placebo for amelioration of anxiety symptoms in patients with GAD. A systematic literature search was performed using databases such as MEDLINE and EMBASE and other sources. The main outcome was Hedges' g for continuous scores. We used a random-effects model. Heterogeneity was evaluated with the I (moderate heterogeneity was assumed if I was >50% and high heterogeneity if I was >75%) and the χ-test (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|